Efficacy And Safety Of Ritlecitinib In Alopecia Areata: A Systematic Review And Meta-Analysis

July 2024

Shaikha Salah Alhaj, Amani AlFalasi, Mohamed Ahmed, Sajad Allami

ritlecitinib alopecia areata SALT scores hair regrowth placebo adverse events

TLDR Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.

This systematic review and meta-analysis evaluated the efficacy and safety of Ritlecitinib, an oral drug targeting Janus Kinase 3 and TEC kinase family, for treating Alopecia Areata (AA). The analysis included 4 studies with a total of 411 patients, of which 205 received Ritlecitinib. The results showed a significant improvement in the Severity of Alopecia Tool (SALT) scores for patients treated with Ritlecitinib compared to placebo, with a mean difference of 30.58 (P < 0.00001). The pooled risk ratio for adverse events was 1.27, indicating no significant increase in adverse events compared to placebo. The study concludes that Ritlecitinib is a potentially effective treatment for AA, but further research is needed to fully understand its potential.

View this study on dx.doi.org →

Discuss this study in the Community →

Research cited in this study

12 / 12 results

research Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the Allegro Phase 2b/3 Study

September 2023 in “Dermatology and therapy”

Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.

research Efficacy and Safety of Ritlecitinib in Adolescents with Alopecia Areata: Results from the ALLEGRO Phase 2b/3 Randomized, Double-Blind, Placebo-Controlled Trial

48 citations , July 2023 in “Pediatric Dermatology”

Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.

research A Plain Language Summary on Ritlecitinib Treatment for Adults and Adolescents with Alopecia Areata

7 citations , July 2023 in “Immunotherapy”

Ritlecitinib works well and is safe for treating alopecia areata.

research Janus Kinase Inhibitors For Alopecia Areata

12 citations , June 2023 in “JAMA network open”

JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.

research Safety of Janus Kinase Inhibitors in Patients with Alopecia Areata: A Systematic Review

3 citations , May 2023 in “Clinical drug investigation”

JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.

research Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial

227 citations , April 2023 in “The Lancet”

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

research Adverse Events in Patients Treated With Jak-Inhibitors for Alopecia Areata: A Systematic Review

2 citations , April 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”

JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.

research Epidemiological Trends in Alopecia Areata at the Global, Regional, and National Levels

11 citations , July 2022 in “Frontiers in immunology”

Cases of alopecia areata and its impact on life quality rose globally, but when adjusted for age, the rates decreased, especially in poorer regions.

research A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of the Oral Janus Kinase Inhibitors Ritlecitinib and Brepocitinib in Alopecia Areata: 24-Week Results

138 citations , March 2021 in “Journal of the American Academy of Dermatology”

Ritlecitinib and brepocitinib effectively regrow hair in alopecia areata patients.